Drug intelligence / Profile preview

SIBP-A17

Development stage: Phase 1
Lead developer: Shanghai Institute of Biological Products
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SIBP-A17 is an intravenously administered antibody-drug conjugate (ADC) targeting ERBB2 (also known as HER2), under development by Shanghai Institute of Biological Products. It is being investigated for the treatment of advanced solid tumors, including late-stage, metastatic, unresectable/inoperable cases and those requiring second-line therapy or greater. The drug is currently in phase 1 clinical trials in China to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor efficacy. The mechanism of action involves inhibition of ERBB2/HER2 signaling pathways[1][2][3][4].

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on SIBP-A17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIBP-A17.

Explore the full profile